Placing

10 May 2010

                             Scancell Holdings Plc                             

                                (the "Company")                                

                                    Placing                                    

Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer
vaccines, announces it has raised approximately £24,000 (before expenses) by
way of a placing of 53,333 New Ordinary Shares of 0.1p each (`Placing Shares')
at a price of 45p (the `Placing') with Wilton International Marketing Limited.

Admission and commencement of dealings in the New Ordinary Shares to be issued
under the Placing are expected to take place at 8.00 a.m. on 11 May 2010. There
will be a total of 15,926,659 Ordinary Shares in issue following Admission of
the Placing Shares.

The Directors of the issuer accept responsibility for this announcement.

                                    -ENDS-                                     

For Further Information:

David Evans                    Scancell Holdings Plc     + 44 774 008 4452   
                                                                             
Kirsty Corcoran/John Bick      Hansard Communications    + 44 207 245 1100   
                                                                             
Ross Andrews / Tom Rowley      Zeus Capital              + 44 161 831 1512   

About Scancell:

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and is expected to enter clinical trials in 2010.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.